DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



[Rifaximin--a non-resorbable antibiotic with many indications in gastroenterology].

Author(s): Rabenstein T, Fromm MF, Zolk O

Affiliation(s): Innere Medizin und Gastroenterologie, Diakonissen-Stiftungs-Krankenhaus Speyer. thomas.rabenstein@diakonissen.de

Publication date & source: 2011-02, Z Gastroenterol., 49(2):211-24. Epub 2011 Jan 11.

Publication type: English Abstract; Review

Rifaximin, a non-resorbable broadband antibiotic, was approved in Germany 2 years ago for the treatment of traveller's diarrhoea caused by non-invasive enteropathogens. On account of the very good tolerance and the high efficacy against almost all enteropathogens this pharmaceutical, which has been available for 25 years, bears a high potential in many other indications which are currently under clinical investigations, including: symptomatic uncomplicated diverticular disease, Clostridium difficile-associated diarrhoea and pseudomembranous colitis, small bowel intestinal bacterial overgrowth, irritable bowel syndrome and hepathic encephalopathy. The present overview demonstrates potential indications in the field of gastroenterology and critically reviews the significance of rifiximin in the treatment of these diseases based on the latest clinica data. (c) Georg Thieme Verlag KG Stuttgart . New York.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017